In melanoma mouse models, the combined application of anti-CTLA-4 monoclonal antibody (ipilimumab) and IL-15 significantly enhances NK cell activation and improves their cytotoxic effects against B lineage acute lymphoblastic leukemia cell lines (Nalm-6) [90]. The gene discussed is CTLA4; the disease is melanoma.